Incyte (INCY) PT Bumped to $115 at Leerink as Gilead's (GILD) Momelotinib Disappoints
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Leerink Partners analyst Michael Schmidt reiterated an Outperform rating and bumped his price target on Incyte (NASDAQ: INCY) to $115.00 (from $101.00) as Gilead Sciences' (NASDAQ: GILD) momelotinib disappoints.
Schmidt commented, "Today GILD (MP) reported top-line results from two Phase III studies evaluating momelotinib, its JAK1/2 inhibitor for patients with myelofibrosis (MF): SIMPLIFY-1 and SIMPLIFY-II. Results from both trials are disappointing, in our view making it highly unlikely that GILD would be able to obtain regulatory approval. Removal of this uncertainty on the revenue outlook of INCY's key commercial product (see our recent deep-dive here: LINK), combined with increasing prospects of a repatriation holiday should make the company more attractive as an acquisition target. While we assumed only a modest success probability for momelotinib, our prior scenario analysis suggested 7-22% downside potential to INCY's valuation in a rage of momelotinib success scenarios. Raising our PT to $115 (from $101)."
Shares of Incyte closed at $100.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MKM Partners Raises Price Target on Finisar (FNSR) to $43 Following 2Q
- Jefferies Raises Price Target on Casey's General Stores (CASY) Following 2Q Earnings Report
- KLR Group Cuts Price Target on Bill Barrett (BBG) to $9; Reiterates Buy
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, FDA
Related EntitiesDefinitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!